• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤微环境对肝内胆管癌预后的影响:肿瘤周围纤维免疫界面的鉴定。

Prognostic impact of the tumour microenvironment in intrahepatic cholangiocarcinoma: identification of a peritumoural fibro-immune interface.

机构信息

Université Paris Cité, Centre de Recherche Sur L'Inflammation (CRI), INSERM, U1149, Paris, France.

AP-HP.Nord, Department of Pathology, FHU MOSAIC, SIRIC InsiTu, DMU DREAM, Beaujon Hospital, 100 Boulevard du Général Leclerc, 92110, Clichy, France.

出版信息

Virchows Arch. 2024 Nov;485(5):901-911. doi: 10.1007/s00428-024-03922-5. Epub 2024 Sep 6.

DOI:10.1007/s00428-024-03922-5
PMID:39242455
Abstract

The tumour microenvironment (TME) of intrahepatic cholangiocarcinoma (iCCA) is complex and plays a role in prognosis and resistance to treatments. We aimed to decipher the iCCA TME phenotype using multiplex sequential immunohistochemistry (MS-IHC) to investigate which cell types and their spatial location may affect its prognosis. This was a retrospective study of 109 iCCA resected samples. For all cases, we used an open-source software to analyse a panel of markers (αSMA, FAP, CD8, CD163) by MS-IHC for characterize the different TME cells and their location. RNA sequencing was performed to determine the main iCCA transcriptomic classes. The association of the TME composition with overall survival (OS) was assessed by univariate and multivariate analyses. A high proportion of activated fibroblasts (FAP +) was significantly associated with poor OS (HR = 2.33, 95%CI = 1.43-3.81, p = 0.001). CD8 T lymphocytes excluded from the epithelial compartment were significantly associated with worse OS (HR = 1.86, 95% CI = 1.07-3.22, p = 0.014). The combination of a high proportion of FAP + fibroblasts and CD8 T lymphocytes excluded from the epithelial compartment, observed in 21 cases (19%), was significantly associated with poor OS on univariate (HR = 2.49, 95% CI = 1.44-4.28, p = 0.001) and multivariate analyses (HR = 2.77, 95% CI = 1.56-4.92, p < 0.001). In these cases, CD8 T lymphocytes were predominantly located at the tumour/non-tumour interface (19/21, 90%), and an association with the transcriptomic inflammatory stroma class was observed (10/21, 48%). Our results confirm the TME prognostic role in iCCA, highlighting the impact in the process of spatial heterogeneity, especially cell colocalization of immune and fibroblastic cells creating a peritumoural fibro-immune interface.

摘要

肝内胆管癌(iCCA)的肿瘤微环境(TME)复杂,对预后和治疗耐药性有影响。我们旨在使用多重连续免疫组化(MS-IHC)来破译 iCCA TME 表型,以研究哪些细胞类型及其空间位置可能影响其预后。这是一项对 109 例 iCCA 切除样本的回顾性研究。对于所有病例,我们使用开源软件分析了一组标记物(αSMA、FAP、CD8、CD163)的 MS-IHC,以描绘不同的 TME 细胞及其位置。进行 RNA 测序以确定主要的 iCCA 转录组类别。通过单变量和多变量分析评估 TME 组成与总生存期(OS)的关联。高比例的活化成纤维细胞(FAP+)与较差的 OS 显著相关(HR=2.33,95%CI=1.43-3.81,p=0.001)。排除在上皮细胞外的 CD8 T 淋巴细胞与较差的 OS 显著相关(HR=1.86,95%CI=1.07-3.22,p=0.014)。在 21 例(19%)病例中观察到高比例的 FAP+成纤维细胞和排除在上皮细胞外的 CD8 T 淋巴细胞的组合,与单变量(HR=2.49,95%CI=1.44-4.28,p=0.001)和多变量分析(HR=2.77,95%CI=1.56-4.92,p<0.001)显著相关。在这些病例中,CD8 T 淋巴细胞主要位于肿瘤/非肿瘤界面(19/21,90%),并观察到与转录组炎症基质类别的关联(10/21,48%)。我们的结果证实了 TME 在 iCCA 中的预后作用,强调了空间异质性过程的影响,特别是免疫和成纤维细胞的细胞共定位,形成了肿瘤周围的纤维-免疫界面。

相似文献

1
Prognostic impact of the tumour microenvironment in intrahepatic cholangiocarcinoma: identification of a peritumoural fibro-immune interface.肿瘤微环境对肝内胆管癌预后的影响:肿瘤周围纤维免疫界面的鉴定。
Virchows Arch. 2024 Nov;485(5):901-911. doi: 10.1007/s00428-024-03922-5. Epub 2024 Sep 6.
2
Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma.术前淋巴细胞/ C-反应蛋白比值及其与 CD8 肿瘤浸润淋巴细胞的相关性可作为预测肝内胆管细胞癌切除术后预后的指标。
Surg Today. 2021 Dec;51(12):1985-1995. doi: 10.1007/s00595-021-02295-5. Epub 2021 May 19.
3
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma.肝内胆管癌免疫微环境中的临床预后因子和靶点。
Oncoimmunology. 2024 Oct 1;13(1):2406052. doi: 10.1080/2162402X.2024.2406052. eCollection 2024.
4
Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.爱泼斯坦-巴尔病毒相关肝内胆管癌的临床病理特征、肿瘤免疫微环境及基因组格局
J Hepatol. 2021 Apr;74(4):838-849. doi: 10.1016/j.jhep.2020.10.037. Epub 2020 Nov 17.
5
Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma.肝外胆管癌患者肿瘤浸润的炎症和免疫细胞。
Br J Cancer. 2018 Jan;118(2):171-180. doi: 10.1038/bjc.2017.401. Epub 2017 Nov 9.
6
Cancer-associated fibroblast senescence and its relation with tumour-infiltrating lymphocytes and PD-L1 expressions in intrahepatic cholangiocarcinoma.癌相关成纤维细胞衰老及其与肝内胆管癌肿瘤浸润淋巴细胞和 PD-L1 表达的关系。
Br J Cancer. 2022 Feb;126(2):219-227. doi: 10.1038/s41416-021-01569-6. Epub 2021 Oct 6.
7
Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.肝内胆管癌中肿瘤微血管对预后的影响:与肿瘤浸润淋巴细胞的关系。
Mod Pathol. 2021 Apr;34(4):798-807. doi: 10.1038/s41379-020-00702-9. Epub 2020 Oct 19.
8
Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma.研究不同预后危险因素的胆管癌患者群体在转录和免疫方面的差异。
Cancer Med. 2024 Aug;13(16):e70135. doi: 10.1002/cam4.70135.
9
Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.整合分析揭示了肝内胆管癌亚型的不同特征。
Liver Int. 2024 Sep;44(9):2477-2493. doi: 10.1111/liv.16015. Epub 2024 Jun 25.
10
Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma.CD8 + T细胞分布在肝内胆管癌中的预后影响及其与HLA I类表达的关联
Surg Today. 2020 Aug;50(8):931-940. doi: 10.1007/s00595-020-01967-y. Epub 2020 Feb 10.

本文引用的文献

1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
2
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).肿瘤免疫微环境与胆管癌的当前免疫治疗(综述)。
Int J Oncol. 2023 Dec;63(6). doi: 10.3892/ijo.2023.5585. Epub 2023 Oct 27.
3
Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma.空间免疫表型可预测肝内胆管癌的临床结局。
JHEP Rep. 2023 Apr 15;5(8):100762. doi: 10.1016/j.jhepr.2023.100762. eCollection 2023 Aug.
4
Immunobiology of cholangiocarcinoma.胆管癌的免疫生物学。
J Hepatol. 2023 Sep;79(3):867-875. doi: 10.1016/j.jhep.2023.05.010. Epub 2023 May 16.
5
Heterogeneity of Cholangiocarcinoma Immune Biology.胆管癌免疫生物学的异质性。
Cells. 2023 Mar 8;12(6):846. doi: 10.3390/cells12060846.
6
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.在肝癌微环境中鉴定决定免疫治疗疗效的肿瘤免疫屏障。
J Hepatol. 2023 Apr;78(4):770-782. doi: 10.1016/j.jhep.2023.01.011. Epub 2023 Jan 26.
7
Fibroblast activation protein-based theranostics in pancreatic cancer.基于成纤维细胞活化蛋白的胰腺癌诊疗一体化
Front Oncol. 2022 Oct 3;12:969731. doi: 10.3389/fonc.2022.969731. eCollection 2022.
8
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.基于新型微环境的肝内胆管癌分类及其治疗意义。
Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18.
9
Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review.基于成纤维细胞激活蛋白的癌症研究治疗学:最新综述。
Theranostics. 2022 Jan 9;12(4):1557-1569. doi: 10.7150/thno.69475. eCollection 2022.
10
Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma.促纤维增生性基质在肝内胆管癌中的预后价值
Mod Pathol. 2021 Feb;34(2):408-416. doi: 10.1038/s41379-020-00656-y. Epub 2020 Aug 28.